Loading...
•
Dec 31, 2021
Bicycle Q4 2021 Earnings Report
Bicycle Therapeutics reported financial results for the fourth quarter and full year ended December 31, 2021.
Key Takeaways
Bicycle Therapeutics reported their Q4 2021 financial results, highlighting clinical progress across their pipeline and a strong cash position of $438.7 million expected to provide financial runway through 2024.
BT8009 and BT5528 demonstrated anti-tumor activity in two tumor types.
Interim results from Phase I trial of BT8009 to be presented at a medical meeting.
Expansion cohorts in clinical trial of BT5528 to be initiated this year.
BT7480 entered the clinic in the fourth quarter of 2021.
Forward Guidance
Bicycle Therapeutics plans to advance clinical programs, expand discovery efforts and early development pipeline, supported by a strong balance sheet with sufficient cash to fund initiatives and support operations through 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...